NeuroPace Inc (NASDAQ:NPCE), a medical device company focused on treating drug-resistant epilepsy, reported financial results for the fourth quarter and full year 2025 that surpassed analyst expectations on the top line. The company also reiterated its financial outlook for 2026, providing investors with a clear view of its expected trajectory as it focuses exclusively on its core neuromodulation business.
Earnings and Revenue Versus Estimates
The company's performance for the final quarter of 2025 showed continued strong commercial execution. NeuroPace reported total revenue of $26.6 million, which represents a 24% increase compared to the fourth quarter of 2024. This figure came in ahead of the analyst consensus estimate of approximately $25.3 million.
On the bottom line, the company reported a net loss per share of $0.08. This result was notably better than the estimated loss per share of $0.15 that analysts had projected. The improved earnings performance reflects both the revenue beat and expanding gross margins.
Key financial highlights from the report include:
- Q4 2025 Revenue: $26.6M (Actual) vs. $25.3M (Estimate) – A beat of roughly 5%.
- Q4 2025 EPS: -$0.08 (Actual) vs. -$0.15 (Estimate) – A significant beat.
- Full Year 2025 Revenue: $100.0 million, representing 25% growth over 2024.
- Q4 Gross Margin: 77.4%, a 200-basis point improvement year-over-year.
Market Reaction and Price Action
Following the earnings release, NeuroPace's stock saw positive movement in after-hours trading, indicating a favorable initial reception from investors. This reaction is likely driven by the dual beat on revenue and earnings per share, coupled with the reaffirmation of full-year guidance. The company's shares had experienced some pressure in the weeks leading up to the report, making the positive earnings surprise a catalyst for a rebound.
Strategic and Operational Highlights
Beyond the financial figures, NeuroPace outlined several key operational achievements that underpin its future growth strategy. A major focus is the expansion of its flagship RNS System's addressable market. The company submitted a PMA supplement to the FDA seeking an expanded indication for idiopathic generalized epilepsy (IGE), supported by positive data from its NAUTILUS clinical trial.
Furthermore, the company is advancing its software and AI capabilities, having submitted its "Seizure ID" AI tool for FDA review. This tool is designed to help clinicians analyze brain data more efficiently. NeuroPace also received favorable updates to Medicare reimbursement rates for its procedures, which should improve hospital economics and support adoption.
A significant strategic shift is the company's move to discontinue its commercial partnership with DIXI Medical earlier than planned. Beginning in Q1 2026, NeuroPace will report DIXI as a discontinued operation, allowing investors to focus solely on the financial performance of its high-margin, high-growth RNS System business.
2026 Outlook and Comparison to Estimates
Management reiterated its full-year 2026 financial guidance on a continuing operations basis, which excludes the DIXI business. The outlook calls for total revenue between $98 million and $100 million, representing underlying RNS System growth of 20% to 22%. This guidance range is generally in line with the current analyst sales consensus estimate of approximately $100.9 million for the full year.
The company expects its first quarter 2026 revenue to be between $21 million and $22 million, which aligns closely with the analyst estimate of about $22.4 million. For the full year, NeuroPace anticipates an Adjusted EBITDA loss of $9 to $10 million as it continues to invest in commercial expansion, next-generation platform development, and its AI software suite.
Conclusion
NeuroPace's fourth-quarter results demonstrate sustained momentum for its RNS System, with the company beating revenue and earnings estimates. The market's positive after-hours reaction suggests investors are encouraged by the strong execution and the clear path forward outlined for 2026. With a sharpened focus on its core neuromodulation platform, upcoming regulatory milestones, and new AI-driven product launches, NeuroPace is positioning 2026 as a potentially transformative year. The company's ability to maintain robust growth while improving its path to profitability will be a key focus for investors moving forward.
For a detailed look at upcoming earnings dates and analyst estimate revisions, visit the NeuroPace earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
